[A16-43] Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V
Last updated 15.12.2016
Project no.:
A16-43
Commission:
Commission awarded on 04.07.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-33 | Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-12 | Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-16 | Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A16-71 | Saxagliptin + saxagliptin/metformin (Addendum to Commission A16-42 + A16-43) | Commission completed |
Federal Joint Committee (G-BA)
2016-12-15 A G-BA decision was published.